Bioidentical Hormone Therapy, considered.
'Bioidentical' is a marketing word for hormones with the same molecular structure as those the body produces. The legitimate medicine is real; the wellness-industry version of it sometimes is not. Distinguishing the two is the patient's first job.
What 'bioidentical' actually means.
A hormone is bioidentical if its molecular structure matches the human hormone exactly. Estradiol patches, oral micronized progesterone, testosterone cypionate — all FDA-approved, all bioidentical. The word is not synonymous with 'compounded' or 'natural,' though marketing often conflates them.
What is *not* bioidentical: conjugated equine estrogens (Premarin), medroxyprogesterone acetate (Provera), synthetic anabolic steroids. These are pharmacologically distinct and produce different risk and benefit profiles than bioidentical analogues.
Where compounded BHRT differs from FDA-approved BHRT.
Compounded preparations (creams, troches, pellets) allow custom dosing and combinations not available off-the-shelf. The trade-offs: variable absorption, inconsistent dosing across batches, no FDA potency oversight, and frequently no large-scale safety data for the specific preparation.
For most patients, FDA-approved bioidentical products (transdermal estradiol, oral micronized progesterone, transdermal/injectable testosterone) cover clinical needs. Compounded BHRT is appropriate when standard preparations cannot meet a specific clinical requirement — not as a default.
Estrogen and the breast cancer conversation.
The Women's Health Initiative findings (2002) used conjugated equine estrogen plus medroxyprogesterone — not bioidentical. Subsequent analysis showed the combination, route, dose, and timing all matter. Transdermal estradiol with cyclic or continuous oral micronized progesterone, started near menopause, has a substantially different risk profile.
Current thinking: for most healthy women within 10 years of menopause and under 60, bioidentical hormone therapy provides meaningful symptom relief and likely net benefit on bone, cardiovascular, and cognitive endpoints. Individual risk profile (family history, prior cancer, thrombotic history) matters.
Pellets — a closer look.
Subcutaneous pellets deliver estradiol or testosterone over 3–4 months without daily dosing. They are popular and aggressively marketed. The downsides: supraphysiologic peaks early in the cycle, inability to dose-adjust mid-cycle, and dosing protocols that often produce hormone levels well above natural ranges.
For some patients, pellets are convenient and effective. For many, transdermal patches or weekly injections produce more stable levels at lower cost. Ask which delivery best matches the clinical goal — not which is being most heavily promoted at the practice.
Common questions.
Is BHRT safer than 'traditional' HRT?
Bioidentical molecules and delivery routes (transdermal estradiol + oral micronized progesterone) appear to have a more favorable risk profile than older synthetic preparations. Whether *compounded* BHRT is safer than FDA-approved BHRT is unsupported by evidence — it has fewer safeguards.
Do I need testing before starting?
Yes. Hormone panels (FSH, estradiol, progesterone, total/free testosterone, SHBG, thyroid panel), comprehensive metabolic, lipids, and individualized cancer screening (mammogram, prostate as applicable). Symptom assessment guides treatment as much as the numbers.
Pellets vs patches vs creams?
Patches and gels deliver the most physiologic transdermal estradiol levels. Oral micronized progesterone is preferred for endometrial protection and sleep benefits. Pellets are convenient but produce supraphysiologic peaks. Match delivery to the goal.
Will it help with weight gain?
Hormonal weight changes during menopause are partially reversible with BHRT, partially structural. Expect modest improvement in body composition, not dramatic weight loss. Pair with strength training and protein.
How long should I stay on it?
Current guidelines no longer impose a strict 5-year limit. Many women continue indefinitely with periodic risk reassessment. The honest answer: as long as benefits outweigh risks, reassessed annually.